WuXi PharmaTech (Cayman) Inc.
US Elections Calendar ~ Pervez Musharraf ~ Iftikhar Muhammad Chaudhry ~ Other International News
Home / International News / Press Releases / July 09, 2008
WuXi AppTec VP and GM Invited to Join the AAMI Standards Board

Top News

Karnataka High Court orders Ramoji Rao to appear in Ballari Court

CCEA approves scheme on National Mission on Medicinal Plants

Magnets could keep sharks at bay!

Pammie was first choice for X-Files lead role!

Chidambaran says government to speed up reforms

ICC chief Haroon Lorgat to meet the media in Colombo

Bossy parents cause older teens to indulge in more sex

Aussies turning in droves to alternative therapies

WuXi AppTec VP and GM Invited to Join the AAMI Standards Board

SHANGHAI, China, July 9 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today proudly announced that Ms. Trabue D. Bryans, Vice President and General Manager of WuXi AppTec's Atlanta Operations, one of the U.S. operating subsidiaries of WuXi PharmaTech (Cayman) Inc., has been invited to join the Association for the Advancement of Medical Instrumentation (AAMI) Standards Board for a three-year term.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

Founded in 1967, the non-profit AAMI is a unique alliance of over 6,000 individuals and 375 organizations from around the world united by the common goal of increasing the understanding and beneficial use of medical instrumentation, as well as the primary resource for the industry, professions, and government for national and international standards. The AAMI standards program consists of over 100 technical committees and working groups that produce Standards, Recommended Practices, and Technical Information Reports for medical devices. Standards and Recommended Practices represent a national consensus and many have been approved by the American National Standards Institute (ANSI) as American National Standards as well as International Standardization Organization (ISO) standards.

Having served as a member of AAMI Sterilization Standards Committee, former co-chair of the AAMI Microbiological Methods Working Group, and expert member to the ISO TC 198 Micro Methods working group, Ms. Bryans will work regularly with more important responsibilities in her new role of directing and supervising all AAMI technical committee activities relating to the national standards program.

''I am very honored to be part of the national standards program, and will do my best to make a worthwhile contribution during my term. As the global medical device industry is rapidly growing and related technologies and products are converging, it is very important to have a set of standards that help regulate the research, development and commercialization of innovative medical devices,'' said Ms. Bryans.

With over 25 years of experience in medical device industry and internationally recognized for her work in microbiology and sterilization and process validation, Ms. Bryans is responsible for all operations of WuXi AppTec's Atlanta facility. She received her B.S. from University of Georgia, and M(ASCP), microbiology technologist certification by the American Society for Clinical Pathology, from Medical College of Georgia. She also completed her M.B.A. course work at Georgia State University.

''We are very proud of Trabue for her expertise and professional status,'' commented Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. ''We are delighted to have such an exceptional individual whose leadership has made tremendous impact on not only national standards but also the medical device testing business of WuXi AppTec. We would like to extend our warm congratulations to Trabue and great support for her new role in AAMI.''

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .

SOURCE WuXi PharmaTech (Cayman) Inc.

International News / Press Release source: PR Newswire
Copyright PR Newswire. All Rights Reserved.

International Business News / Press Releases

China Marine Penetrates New Markets in Shanghai and Guangdong Province and Launches Three New Snack Foods Market-wide
PR Newswire

Suntech to Announce Second Quarter 2008 Financial Results on August 20, 2008
PR Newswire

China Agritech Delivers Fertilizer Shipment to Egypt
PR Newswire

China Wind Systems, Inc. Issues Guidance for Second Quarter and Full Year 2008
PR Newswire

CCID Consulting Forecasts Compound Growth Rate for China's Broadcasting Mobile TV Output
PR Newswire

International Health News / Press Releases

Pharmasset Announces Consummation of $24.18 Million Registered Direct Offering of Common Stock
PR Newswire

Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
PR Newswire

American Stress Levels Reaching an All-Time High
PR Newswire

China Information Security Technology, Inc. Expands PGIS Solution Set With First 120 Emergency Medical Service (EMS) System Contract Win in Shenzhen City
PR Newswire

Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
PR Newswire

International Medical News / Press Releases

Pharmasset Announces Consummation of $24.18 Million Registered Direct Offering of Common Stock
PR Newswire

Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
PR Newswire

/C O R R E C T I O N -- China-Biotics, Inc./
PR Newswire

U.S. Federal Circuit Court of Appeals Rules Patent for ACIPHEX(R) Valid and Enforceable
PR Newswire

U.S. Federal Circuit Court of Appeals Fully Upholds Eisai's Favorable Ruling in Aciphex(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals and Dr. Reddy's Laboratories
PR Newswire